SQZ Biotechnologies Price to Free Cash Flow Ratio 2020-2022 | SQZ

Historical price to free cash flow ratio values for SQZ Biotechnologies (SQZ) since 2020. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
SQZ Biotechnologies Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-31 0.82 0.00
2022-09-30 2.28 $-2.96 0.00
2022-06-30 3.18 $-2.99 0.00
2022-03-31 4.81 $-2.94 0.00
2021-12-31 8.93 $-3.00 0.00
2021-09-30 14.42 $-10.41 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00